Sun Pharma shares gain despite Q2 profit slips 36% YoY | Should you buy, sell or hold? What brokerage says, target price

Sun Pharma shares rose 0.87% despite a 36.4% year-on-year drop in September-quarter net profit to ₹1,988.5 crore. Revenue increased 11.9% to ₹16,198.7 crore, driven by India and innovative medicines, while exceptional US litigation and Organon acquisition costs weighed on earnings.

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to livemint.com's own reporting rather than reproducing it — the excerpt above comes from livemint.com's own feed.